Brief: Onxeo Expands Its Pipeline With New Optimized Lead Ox401 Entering Proof-Of-Concept Preclinical Phase

Valerio Therapeutics SA

20/06/2019 17:33

June 20 (Reuters) - Onxeo SA  C4X.PA :
    * ONXEO EXPANDS ITS PIPELINE WITH NEW OPTIMIZED LEAD OX401
ENTERING PROOF-OF-CONCEPT PRECLINICAL PHASE
    * IN VIVO PROOF-OF-CONCEPT RESULTS ALONE AND IN COMBINATION
WITH
CANCER IMMUNOTHERAPIES ARE EXPECTED BY EARLY Q4 2019
    * PRECLINICAL PROOF-OF-CONCEPT RESULTS SHOWING OX401
EFFICACY,
ALONE AND IN COMBINATION WITH IMMUNOTHERAPY TREATMENTS, ARE
EXPECTED EARLY Q4 2019
    * COMPREHENSIVE PATENT WAS FILED FOR OX401 TO PROTECT
ONXEO'S
INTELLECTUAL PROPERTY RIGHTS ON THIS PRODUCT, ALONE AND IN
COMBINATION WITH CANCER IMMUNOTHERAPIES, UNTIL 2039

Source text for Eikon:  ID:nBw4jdr73a 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))